Conclusions of IBCD 2018, the regulatory science meeting for precision medicine
10 Dec 2018
The 2018 edition of the Innovation and Biomarkers in Cancer Drug Development Conference (IBCD) has gathered over 150 participants from over 15 countries and 3 continents to learn and share about the challenges of new drug development and biomarkers in cancer.
The focus of the IBCD meeting, which involved stakeholders from industry, regulatory agencies, academia and patients, was to explore the practical issues relating to how biomarker assay development could be more effectively integrated into drug development and regulatory approval processes to drive further progress in cancer-related precision medicine, all this benefiting society within a healthcare context.
IBCD offered unprecedented opportunities for cross-stakeholder discussions. Attendees and presenters repeatedly highlighted the need for dialogue-based decisions and a structured approach to biomarker development – from pre-analytical issues to routine use of biomarkers.
The meeting provided solid grounds for the evolution of clinical research towards the development of precision medicine, bringing together all stakeholders’ viewpoints on providing patients with better therapeutic options and access to innovation.
The outcomes from the conference will be published in the European Journal of Cancer and in the Clinical Cancer Research Journal.
To learn about IBCD speakers’ perspective on the conference: check their video’s interview
To watch the IBCD’s presentations: the webcasts will be available soon.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023